HBV Forum 15

E-mail Print

HBV Forum 15 Meeting was held on Thursday, November 6, 2025, in Washington, DC

Materials

pdfAgenda
pdfParticipant List

Introductory Remarks and Program Overview

pdfWelcome, Forum Updates, Program Overview, and Acknowledgments
Ekene Osakwe, Forum for Collaborative Research
Veronica Miller, Forum for Collaborative Research

Steering Committee Co-Chair Welcoming Remarks
Terry Wright
Norah Terrault, Keck School of Medicine of USC

Session I: Roundtable Updates

Rapid Fire Industry Updates
Sue Currie, Virion Therapeutics
Emily Harrison, Precision BioSciences
Kendra Congdon, Tune Therapeutics
Tracy McGregor, nChroma Bio

pdfEMA Updated Guidelines
*Stephanie Buchholz, European Medicines Agency

HBV/MASLD Working Group Update
Harry Janssen, Erasmus University Medical Center

pdfAsian HBV/HDV Endpoints Consensus Meeting Update
Veronica Miller, Forum for Collaborative Research

Open Discussion
All Meeting Participants

Session II: Hepatitis Delta Therapeutics and Assay Development

pdfFeedback from Delta Cure
Pietro Lampertico, University of Milan

pdfIndustry Updates: HDV Therapies and Diagnostics
Todd Corell, Vir Biotechnology
Nancy Shulman, Blue Jay Therapeutics
Marc Windisch, Assembly Biosciences
Jenny Stanton, Gilead Sciences
Jeffrey Glenn, Stanford University
Christian Voitenleitner, Roche Diagnostics International
Gerald Wallweber, Labcorp/Monogram Biosciences

Panel Discussion/Open Discussion
All Speakers +
Jessica Hicks, World Hepatitis Alliance
Audience

Session III: Hepatocellular Carcinoma

pdfWhy HCC? Why Now? (Opening Remarks)
*Loey Lung-Yi Mak, The University of Hong Kong

pdfGlobal HCC Epidemiology, Changing Risk Patterns, and Unmet Medical Needs
Robert Wong, Stanford University School of Medicine

pdfIndustry Updates: Biomarkers
Shivani Mahajan, Helio Genomics
Elle Grevstad, Exact Sciences
Timothy Block, Baruch S. Blumberg Institute

Panel Discussion/Open Discussion
All Speakers +
Mark Sonderup, University of Cape Town
*Alexander Stockdale, University of Liverpool
Yasmin Ibrahim, Hepatitis B Foundation
Audience

Session IV: Gene Editing and Epigenomics

pdfPerspectives and Challenges in in vivo Gene Therapy for HBV: Building a Clinical Program from First-in-Human Trials to a One-and-Done CURE
Ed Gane, University of Auckland

Panel Discussion/Open Discussion
Emily Harrison, Precision BioSciences
Kendra Congdon, Tune Therapeutics
Tracy McGregor, nChroma Bio
Bob Zhang, Epigenic Therapeutics
Man-Fung Yuen, The University of Hong Kong
Mark Sulkowski, Johns Hopkins University School of Medicine
Audience


* Remote Participation